GSK 299423

GSK 299423
Names
	Preferred IUPAC name 6-Methoxy-4-[2-(4-{[(2H-[1,3]oxathiolo[5,4-c]pyridin-6-yl)methyl]amino}piperidin-1-yl)ethyl]quinoline-3-carbonitrile
Identifiers
CAS Number	1352149-24-6 [PubChem];
3D model (JSmol)	Interactive image;
ChemSpider	24751852 ;
PubChem CID	46835136;
UNII	2Q0G81H7FK ;
CompTox Dashboard (EPA)	DTXSID50159279 ;
	InChI InChI=1S/C25H27N5O2S/c1-31-20-2-3-23-22(11-20)21(17(12-26)13-29-23)6-9-30-7-4-18(5-8-30)27-14-19-10-25-24(15-28-19)32-16-33-25/h2-3,10-11,13,15,18,27H,4-9,14,16H2,1H3 Key: NKXJSCXEAVZSMF-UHFFFAOYSA-N ;
	SMILES COc1ccc2c(c1)c(c(cn2)C#N)CCN3CCC(CC3)NCc4cc5c(cn4)OCS5;
Properties
Chemical formula	C25H27N5O2S
Molar mass	461.58 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

GSK 299423 or GlaxoSmithKline 299423 is an antibiotic chemical compound that has been identified as potentially effective in treating patients infected with bacteria expressing the New Delhi metallo-beta-lactamase. The antibiotic inhibits the enzyme topoisomerase, which bacteria need to replicate.^[1]^[2]^[3]

No animal studies have been reported. No application has been made for human clinical trials.^{[citation needed]}

References

^ Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria^{[permanent dead link‍]}," The Wall Street Journal, August 4, 2010
^ Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' Archived 2010-08-16 at the Wayback Machine" Daily Finance, August 6, 2010
^ Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. Bibcode:2010Natur.466..935B. doi:10.1038/nature09197. PMID 20686482. S2CID 205221405. (primary source)

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] Sten Stovall, "Glaxo:New Compound Offers Way To Fight Drug-Resistant Bacteria^{[permanent dead link‍]}," The Wall Street Journal, August 4, 2010

[2] Melly Alazraki, "GlaxoSmithKline Finds Compound That Could Help Fight 'Superbugs' Archived 2010-08-16 at the Wayback Machine" Daily Finance, August 6, 2010

[Bax2010-3] Bax BD, et al. (4 August 2010). "Type IIA topoisomerase inhibition by a new class of antibacterial agents". Nature. 466 (7309): 935–40. Bibcode:2010Natur.466..935B. doi:10.1038/nature09197. PMID 20686482. S2CID 205221405. (primary source)

[1]

[2]

[3]